Tagged with

BioConnection In addition to highlighting company strategies and strengths in our reports, we also like to get a feel for the leaders within the local markets that we cover. We noticed that you have worked for several of the Netherlands’ flagship companies, namely Organon and Octoplus. What was the trajectory that…

Malta   Alan Camilleri, chairman of Malta Enterprise—the government agency responsible for facilitating and stimulating the development of Malta—recalls the words of a foreign investor, who had taken stake in Maltese business. The investor imagined what he would say to other potential promoters, if asked whether they should put their finances…

Nycomed Malaysia Before joining Nycomed you spent a year working at the Drug Control Authority (DCA). What did your regulatory friends say when you told them you were off to join the dark side of working for MNCs? I was a pharmacist by training and the DCA for me was a type…

Invida Malaysia When we spoke to Herbert Dittmar of Bayer, he said that there were no specific challenges in Malaysia that could not be found elsewhere. How do you convince companies of the need for the services offered by Invida? We actually have many companiesseeking to partner with Invida. Invida offers a…

AMCHAM Malaysia Would you give our readers an insight into the government’s attempts to foster a better environment for FDI in Malaysia? Over the last year, the significant development has been the emergence of the Economic Transformation Programme (ETP). Through this initiative Malaysia is attempting to catapult itself out of the ‘middle-income…

Atlantic Healthcare Ltd A key milestone for Atlantic Healthcare was the deal with Isis Pharmaceuticals for alicaforsen in 2007. In 2008, alicaforsen acquired orphan drug status in the U.S.; in 2009, orphan status was granted in Europe. Many companies in the UK have named market access as a key challenge—but is that an…

Merck Sp. z.o.o You joined Merck in September 1996, took gradually increasing positions at Merck, from Medical Representative (1996 – 1998), to Sales and Marketing managing positions and you were ultimately appointed Managing Director Poland in January 2008. What have been the major challenges you faced in almost three years now? Merck in…

Pfizer Polska You have been appointed at the head of Pfizer Poland last December. 2010 is a hot year for the group – even very hot for some of the top management – What has been the most challenging thing for you to deal with in this first year in Poland? The…

Novo Nordisk Pharma Sp. z.o.o Apart from Poland being a 40 million population market, with double digit growth, Mr. Kuczynski of Pierre Fabre was telling us that the main opportunity of the Polish market lies in the many unmet, local medical needs. What are the main specificities of the Polish market in your view and…

PharmaExpert What is PharmaExpert’s role in the Polish pharmaceutical industry? The information that PharmaExpert gathers enables us to give good insight about the evolution of the pharmacists market, the evolution of the prices in the pharma landscape, and of the level of reimbursement, among others. PharmaExpert created a model of explanation…

The Window Conference Center is hosting at least six pharmaceutical events within a month, and has a broad prior history of orchestrating such occasions. How important is the pharmaceutical industry to your business? To speak to the broader situation in the UK (and obviously, that situation is affected by the…

Bayer Co. Malaysia / Bayer Healthcare Malaysi Can you give our readers an outline of Bayer’s background in Malaysia and its current organisational division? Herbert Dittmar (HD): Bayer has been in Malaysia for around fifty years. It established its first legal entity here in the early 1970s and then engaged in a number of acquisitions worldwide including…